Tevogen expanding collaboration with Microsoft and Databricks

Tevogen (TVGN) announced that its artificial intelligence initiative, Tevogen.AI, is expanding its collaboration with Microsoft (MSFT) and Databricks to build the beta version of its foundational PredicTcell model. “We have been extremely fortunate to work with such great organizations like Microsoft and Databricks to build the alpha version of our foundational AI model,” said Mittul Mehta, Chief Information Officer and Head of Tevogen.AI. “Oncology represents one of the most impactful areas for AI in drug discovery, given the complexity of the disease and the limited availability of high-quality datasets.”